Lilly moves beyond blockbuster obesity drugs with $1.2 billion Ventyx buy

By Puyaan Singh Jan 7 (Reuters) - Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the ​companies said on Wednesday, marking the Zepbound maker's latest ‌push to expand beyond its blockbuster diabetes and weight-loss drugs. Ventyx is developing several ‌treatments, including oral therapies for inflammatory bowel diseases such as Crohn's and ulcerative colitis, besides drugs for immunity-related, cardiometabolic and neurodegenerative disorders. One of its drugs i ...